Skip to contentF
Fulcrum Therapeutics, Inc.
F
FULCFulcrum Therapeutics, Inc. Q1 2024 · 10-Q
Revenue$0.00$0.00no prior Q1 2023 on file Net Income-$26.87M-$26.87Mno prior Q1 2023 on file EPS Diluted-$0.43-$0.43no prior Q1 2023 on file Operating Income-$29,834,000— Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
Free Cash Flowderived-$25,312,000— ended Mar 31, 2024 · filed May 13, 2024 · 43 d after period end